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Abstract
Aim To determine the cost-effectiveness of all options for the self-monitoring of blood glucose funded by the National
Health Service, providing guidance for disinvestment and testing the hypothesis that advanced meter features may justify
higher prices.
Methods Using data from the Health and Social Care Information Centre concerning all 8 340 700 self-monitoring of
blood glucose-related prescriptions during 2013/2014, we conducted a cost-minimization analysis, considering both
strip and lancet costs, including all clinically equivalent technologies for self-monitoring of blood glucose, as determined
by the ability to meet ISO-15197:2013 guidelines for meter accuracy.
Results A total of 56 glucose monitor, test strip and lancet combinations were identified, of which 38 met the required
accuracy standards. Of these, the mean (range) net ingredient costs for test strips and lancets were £0.27 (£0.14–£0.32)
and £0.04 (£0.02–£0.05), respectively, resulting in a weighted average of £0.28 (£0.18–£0.37) per test. Systems providing
four or more advanced features were priced equal to those providing just one feature. A total of £12 m was invested in
providing 42 million self-monitoring of blood glucose tests with systems that fail to meet acceptable accuracy standards,
and efficiency savings of £23.2 m per annum are achievable if the National Health Service were to disinvest from
technologies providing lesser functionality than available alternatives, but at a much higher price.
Conclusion The study uncovered considerable variation in the price paid by the National Health Service for self-
monitoring of blood glucose, which could not be explained by the availability of advanced meter features. A
standardized approach to self-monitoring of blood glucose prescribing could achieve significant efficiency savings for the
National Health Service, whilst increasing overall utilisation and improving safety for those currently using systems that
fail to meet acceptable standards for measurement accuracy.
Diabet. Med. 33, 681–690 (2016)
Introduction
Self-monitoring of blood glucose (SMBG) is a fundamental
component of ongoing diabetes self-management, enabling
improved glycaemic control [1], the identification and
confirmed resolution of hypoglycaemia [2] and significant
improvements in health, well-being and all-cause mortality
[3] among those achieving the maintenance of near-normal
blood glucose levels [4]. Yet, whilst the benefits associated
with SMBG are considerable, reaching £150 m in 2010 [5]
and increasing year-on-year [6], so too are the costs. With the
rising prevalence and incidence of diabetes [7], SMBG is now
a major contributor to National Health Service (NHS)
prescribing spending [5,6].
In spite of increased spending on SMBG, as many as 47% of
individuals with Type 1 diabetes mellitus are currently not
having their needs met as a result of SMBG prescribing quotas
that restrict access to strips, with 34% of all quotas resulting
from cost-cutting measures by clinical commissioning groups
[8]. Two-thirds of individuals with SMBG prescribing short-
falls cite a subsequent reduction in their ability to adequately
control their diabetes [8], including reductions in hypo- and
hyperglycaemia detection and adequate checks before driving,
and the ability to monitor glucose levels during periods of
illness. This increases the likelihood of hospitalization, the
principal driver of diabetes-related costs [9].Correspondence to: Simon Leigh. E-mail: sleigh@liv.ac.uk
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Given the numerous attempts by clinical commissioning
groups to regulate escalating SMBG costs [10–12], and the
‘postcode lottery’ that currently exists with respect to
SMBG prescribing, in terms of both the volume of testing
and the systems recommended for use [8,13], it would
seem unlikely that each of the many technologies currently
subject to reimbursement by the NHS are of equal clinical
and cost-effectiveness. As such, a coordinated and stan-
dardized approach to SMBG prescribing, informed by cost-
effectiveness, has the potential to achieve significant
efficiency savings for the NHS, without compromising
care. These savings may then be re-allocated to improve
diabetes management, either through increasing access to
cost-effective options for SMBG, or as previously sug-
gested, by increasing access to publically funded insulin
pumps [14].
The present health economic assessment, the first of its
kind, aims to provide decision-makers with a framework to
assess the multitude of SMBG technologies currently avail-
able and in use within the NHS, based entirely on their
respective costs, accuracy and clinical benefits, in order to
achieve the greatest benefit per NHS pound spent, reduce
escalating SMBG prescribing costs, and improve the overall
standard of care for those with diabetes mellitus.
Materials and methods
Choice of economic model
A cost-minimization analysis was conducted from an NHS
perspective in order to assess the costs and clinical charac-
teristics of the numerous SMBG technologies currently
funded by the NHS. This methodology is a form of cost-
effectiveness analysis, whereby a predetermined objective, in
this case the measurement of blood glucose concentrations, is
achieved via the adoption of the least costly of one or more
‘clinically equivalent technologies’.
As every blood glucose meter is slightly different, no two
tests of the same droplet of blood are likely to produce the
same result. This is partly attributable to the large array of
interfering factors which may influence the results, including
blood oxygen concentrations and humidity [15], haematocrit
[16], temperature [15] and altitude [17], but also the fact that
no technology is 100% accurate, with measurement biases of
between (-) 14.1%and (+) 12.4%, commonwithin the glucose
monitors currently in usewithin theNHS [18]. For this reason,
we defined ‘clinical equivalence’ as the ability to conform to
the recently updated international standard formeter accuracy
currently adopted by the NHS, the Conformite Europeene
ISO-15197:2013 guidelines for blood glucose measurement.
Specifically, monitors must show that 95% of their results are
within 0.83 mmol/l of the results of the manufacturer’s
measurement procedure at glucose concentrations of
<4.2 mmol/l, and within 15% for glucose concentrations
≥5.5 mmol/l. Any SMBG systems identified that fell short of
these accuracy criteria, as determined by the recent evaluations
of 56 blood glucose monitors by Khan et al. [19] and
Freckman et al. [18,20] were excluded from our primary
analysis, because of the increased likelihood of significant
morbidity resulting from incorrect insulin dosing [21] and
hypoglycaemia detection [22].
Data collection and model development
Data were obtained from the Health and Social Care
Information Centre (HSCIC) [23], concerning all 8 340
700 prescriptions dispensed in England between April 2013
and March 2014, relating solely to the measurement of blood
glucose. From the HSCIC database we identified every brand
of blood glucose test strips and lancets dispensed over this
period, the number of prescriptions for each, and their
associated net ingredient costs, equal to the purchase price
before the deduction of confidential discounts, negotiated
with manufacturers.
The British National Formulary was used to identify which
blood glucose monitors dispensed during the study period
were still subject to NHS reimbursement and also to
determine which monitors were compatible with each brand
of available test strips, as strips may often be compatible with
more than one brand of glucose monitor. We subsequently
referred to the user manuals for every glucose monitor
identified in order to determine the brand of disposable
lancets compatible with the ‘stock’ lancing device provided
with each glucose monitor.
Combining the net ingredient costs of each lancet and
SMBG test strip product, we estimated the ‘cost per test’
What’s new?
• This study is the first of its kind to combine information
concerning costs of self-monitoring of blood glucose,
meter accuracy (ISO-15197:2013) and advanced meter
feature availability, for every self-monitoring of blood
glucose system funded by the National Health Service.
• The study uses data detailing exactly how all 581
million self-monitoring of blood glucose test strips and
150 million lancets prescribed were distributed between
brands.
• During the study period, one in 14 (42 million) self-
monitoring of blood glucose tests were performed with
systems that fail to meet ISO-15197:2013 accuracy
standards, at a cost of £12 m.
• Self-monitoring of blood glucose prescribing costs
varied by up to 19 pence per test, depending on brand.
• Annual self-monitoring of blood glucose efficiency
savings of £23.2 m are achievable without compromis-
ing care.
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associated with each available test strip, lancet and monitor
combination funded by the NHS during the study period.
Unlike previous analyses [15], the expected costs of training
individuals to use glucose monitors were excluded, as
training will be necessary for all glucose monitoring systems,
resulting in no incremental difference in costs between one
system and another.
Taking account of advanced meter features
Because diabetes mellitus has a heterogeneous patient profile,
affecting people of all ages and levels of comorbidity, it is
reasonable to assume that those practising SMBG will
exhibit widely varying underlying health states. As such,
the clinical needs of these individuals are also likely to be
very diverse, requiring varying levels of care, support and
assistance in order to achieve the greatest effect.
After a comprehensive review of the SMBG literature, we
identified seven advanced features of glucose monitors,
currently available in varying degrees, which were deemed
likely to be of clinical importance, albeit in varying degrees,
to SMBG users: (1) notifications and alarms to remind to test
blood sugar; (2) alternate site testing; (3) ability to measure
ketones; (4) bolus insulin adjustment guidance; (5) audible
output for those registered as blind; (6) 7- and 14-day +
glucose level average; and (7) option to download and
analyse blood glucose data via USB data transfer.
We subsequently determined which SMBG systems pro-
vided access to each of these features, identifying any ‘within-
group’ variations in the price of such systems, in order to
determine the most cost-effective options available within
each subgroup. For any systems that were strictly dominated,
that is, they were not only more expensive but also provided
fewer advanced features than similar alternative options, we
provided recommendations for disinvestment and for switch-
ing usage to such lower-priced options. In doing so, we
estimated the overall budget impact of switching, along with
any additional benefits that may be accrued as a result of
improved access to a greater number of advanced meter
features that were previously unavailable.
Because our analysis is based on net ingredient costs and
not the confidentially negotiated ‘true price’ paid by NHS
purchasers, we additionally provide a summary table listing
the discounts that must be achieved when purchasing SMBG
strips, and deducted from the listed net ingredient cost, such
that clinically equivalent yet initially more expensive tech-
nologies, become as cost-effective as lower-priced alterna-
tives.
Results
Systems for SMBG currently in use within the NHS
Forty-four brands of SMBG test strips were reimbursed
through the NHS during the analysis period, compatible with
51 blood glucose monitors and representing 22 manufactur-
ers. This resulted in a total of 56 glucose monitor, test strip
and lancet combinations. Of these, we omitted five brands of
SMBG strips no longer available as part of the NHS standard
of care (Accucheck Active, Accucheck Advantage, Accucheck
Compact, Onetouch Ultra and Sensocard) and a further eight
glucose monitors (Gluco RX Original, IME-DC, One touch
Verio Pro, Contour XT, Microdot +, Element, GlucoRX
Nexus Voice (TD-4280) and the Omnitest 3) because of
failure to comply with ISO-15197:2013 meter accuracy
standards, leaving a total of 38 suitable test strip and glucose
monitor combinations.
The mean (range) cost of test strips and lancets for the 38
applicable glucose monitor and test strip combinations were
£0.27 (£0.14–£0.32) and £0.04 (£0.02–£0.05) per test,
respectively. This resulted in a sample average of £0.31 per
SMBG test, but after taking account of the 4:1 prescribing
ratio of SMBG strips to lancets, as demonstrated by the
HSCIC, this reduced to ~£0.28 per test. The variation in costs
was also substantial, with a range of £0.19 per test (£0.18–
£0.37), as shown in Table 1, suggesting that some SMBG
systems have a list price more than double that of available
alternatives.
Does the availability of advanced meter features result in a
higher price per test?
As shown in Fig. 1, the distribution of ‘cost per test’ for the
38 applicable SMBG systems listed in Table 1 was subject
to considerable positive skew. As such, the vast majority of
blood glucose tests performed over the study period (84.%)
were carried out at a cost of £0.34–£0.36 per test, whilst
SMBG systems offering a total of four advanced meter
features were, on average, priced equivalent to those
providing just one, at £0.30 per test. After adjusting for
the capability of SMBG systems to provide specific
advanced features, a significant degree of ‘within-group’
variation in price remained, as shown in Fig. 2, nullifying
our prior hypothesis of a positive correlation between
market price and the availability of advanced meter
features.
Usage of SMBG systems failing to meet ISO-15197:2013
safety standards
Since initially being awarded Conformite Europeene mar-
keting approval, a total of eight NHS-funded SMBG systems
failed to conform to internationally accepted standards for
blood glucose measurement accuracy, when independently
re-tested under laboratory conditions (Table 2). These sys-
tems accounted for ~41.6 m of the 581.2 m blood glucose
tests funded during the study period, suggesting that almost
one in 14 tests (7.2%) were performed with technologies
known to frequently produce erroneous results, at a cost of ~
£12 m.
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Can the NHS achieve efficiency savings without
compromising care?
We identified 12 opportunities whereby disinvesting in one
SMBG system and switching users to a cheaper alternative, at
the very least providing the same functionality, would not
only reduce NHS prescribing costs, but in doing so, poten-
tially improve the level of glucose monitor functionality
experienced by users. If the NHS were to implement these
disinvestments, as proposed in Table 3, efficiency savings of
~£23.2 m per year are achievable, whilst four out of 12 of
these will also result in improved access to advanced meter
features. In the event that these switches are not made, we
calculated the absolute minimum discounts that must be
achieved and deducted from the list price when purchasing
SMBG strips, such that those that are currently more
expensive can become as cost-effective as lower priced
alternatives (Table 4).
Discussion
To the best of our best knowledge, this cost-minimization
analysis is the first-of-its-kind to combine information
regarding the complete costs of SMBG, including both test
strips and lancets, meter accuracy and the functional capa-
bilities of systems, providing a nationally representative
review of SMBG cost-effectiveness. Our results clearly show
that improvements are possible with respect to the current
provision of SMBG services, with the potential for both
reduced prescribing costs and advances in the standard of
care delivered. Of the 581 million blood glucose tests
undertaken during the study period, variations in procure-
ment costs were considerable, with a mean (range) cost of
£0.19 per test (£0.18 to £0.37). Furthermore, significant
within-group variations in costs remained even after adjust-
ing for the presence of advanced meter features, with those
providing a total of four advanced features priced equal to
those providing just one.
Our results highlight numerous opportunities whereby
switching from cost-ineffective technologies to cheaper
more-effective alternatives would not only increase access
to advanced meter features, but also reduce SMBG prescrib-
ing expenditure by ~£23.2 m per year. These savings may
then be dedicated to improving other areas of diabetes
management, including the provision of >14 500 additional
insulin pumps per year [24], moving the NHS closer to the
standards set by the rest of Europe [25]. Given that 34% of
SMBG prescribing restrictions were reported by Diabetes UK
to be the direct result of cost-cutting measures by providers,
any savings generated may also then be used to reduce the
unmet need that the one-in-two (47%), or ~116 000 [25]
individuals with Type 1 diabetes, currently face. Previous
research has shown that a restriction in the volume of blood
glucose testing is likely to affect an individual’s ability to
adequately control blood sugar levels [8], including detection
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of hypo- and hyperglycaemia, management of sick days, and
the ability to make adjustments with respect to exercise, food
and illness [8]. Through increasing access to more
cost-effective strips at the expense of reducing the current
reliance on cost-ineffective systems, we propose that this will
improve disease management, and as such, reduce hospital-
ization, the primary driver of diabetes-related costs [9].
Our findings are consistent with observations in other
publicly funded healthcare systems, with prescribing costs
in New Zealand falling by >40% after the implementation
of a more market-led competitive-bidding, winner-takes-all
approach to SMBG cost-minimization in 2013 [26]. In
Italy, experimental findings have confirmed a greater
overall utilization of test strips, a significantly reduced
number of hospitalizations and a reduced overall duration
of hospitalization after a coordinated approach to SMBG
prescribing [27]. Recent NHS activity has also shown,
albeit disparately, that a number of clinical commissioning
groups throughout England have also been implementing
similar approaches to SMBG cost-cutting and prioritiza-
tion. The West Hampshire [10], Berkshire West [11] and
Wirral [12] clinical commissioning groups are just some of
those publishing local recommendations for SMBG pre-
scribing, suggesting that, although limited at present,
FIGURE 1 National Health Service utilisation of self-monitoring of blood glucose (SMBG) systems at varying cost per test.
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FIGURE 2 Within-group variations in price per test for self-monitoring of blood glucose systems providing advanced features.
Table 2 Self-monitoring of blood glucose systems that fail to meet ISO
standards for blood glucose testing accuracy
Current SMBG
system
Current
utilisation
Current annual
cost
Contour XT 20 008 500 £6.8 m
GlucoRX Nexus
Voice
12 326 450 £2.84 m
Microdot + 3 505 800 £806,300
Omnitest 3 3 194 300 £766,600
One touch Verio Pro 1 776 900 £604,100
Gluco RX Original 610 700 £134,400
Element 123 600 £29,700
IME-DC 13 100 £3,700
Total 41.6 m £12 m
SMBG, self-monitoring of blood glucose.
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awareness and support of the need for a coordinated
approach is growing. Results from the West Hampshire
clinical commissioning group [10] estimated yearly savings
of ~£35,500 through replacing expensive single-use lancets
(Fastclix, Multiclix and Softclix), with lower-cost alterna-
tives, including Apollo twist or Gluco RX lancets. In the
case of the Wirral clinical commissioning group, savings of
up to £125,000 per year were predicted after the switching
of just 50% of SMBG users to either the Supercheck 2 or
GlucoRX Nexus [12], with the authors also emphasizing
using meter switching as an opportunity to review the use
of blood glucose testing and to identify those with the
greatest need for educational messages and support to
further improve cost-effectiveness.
The finding that £12 m was dedicated to providing almost
42 million SMBG tests with systems that fail to comply with
ISO-15197:2013 accuracy standards is not only important
with respect to health service efficiency, but also, even more
importantly, with regard to user safety and disease manage-
ment. Although it is generally accepted that off-the-shelf
strips fail to replicate the performance of pre-market
approval registration data, and that after regulatory approval
the quality and reliability of ‘off brand’ SMBG strips
deteriorates, some brands clearly deteriorate faster than
others. If left unchanged, the one in 14 individuals currently
informing their diabetes management with use of these most
inaccurate SMBG systems, will probably continue to face a
significantly increased risk of adverse events, including
incorrect insulin dosing, hypoglycaemia and long-term
increases in HbA1c [21,22].
Given the increasing prevalence and costs of diabetes
management [7] and growing pressures to increase the
volume of blood glucose testing, the prevailing question, as
expressed previously [26], is whether the objective of
publicly funded diabetes care is to improve survival and
health-related quality of life, or to encourage user choice.
Subject to a finite budget, this necessitates a trade-off
between the two, with the desires of some currently
effectively pricing out the clinical needs of others. In the
absence of a ‘standard reimbursement offer’ from the NHS
where users may contribute towards the costs of procuring
more expensive technologies, and given the imminent avail-
ability of increasingly novel SMBG devices, including the
bloodless Abbott Freestyle Libre Flash, this question becomes
of increasing relevance, as the availability of such SMBG
systems will almost certainly reset the benchmark of expec-
tations for those with diabetes mellitus.
The present study has a number of limitations, largely
concerning the a priori assumptions on which the analysis was
based. Firstly, we assumed that lancets would be used as
recommendedbyclinical guidelines, that is, as single-use items.
In reality, and as referenced by the observed 4:1 prescribing
ratio of strips to lancets, it is possible that lancets may be used
numerous times before discarding, thereforemarginally reduc-
ing the real-world cost per test for all SMBG systems.
Furthermore, some features of SMBG systems, including 7-
and 14-day averages and ketone testing were considered
clinically relevant, whereas others, including slimline and
ergonomic design were not. In doing so, we recognize the
variable value of these features to the average SMBG user.
Table 3 Opportunities for disinvestment: implications to users and budget impact
Current SMBG
system
Current
utilisation
Current
annual cost
Recommended
SMBG system
Cost difference
from switching Patient impact from switching
Accucheck
mobile
37 373 000 £13.83 m Wavesense Jazz (-) £5.23 m No difference
BG Star 6 891 000 £2.27 m Wavesense Jazz (-) £685,100 No difference
Onetouch
Verio
1 776 923 £604,100 Wavesense Jazz (-) £195,400 No difference
Onetouch
Verio IQ
1 776 923 £604,100 Wavesense Jazz (-) £195,400 No difference
Myglucohealth 5400 £1,900 Wavesense Jazz (-) £700 No difference
Contour 65 343 400 £22.2 m Wavesense Jazz (-)£6.53 m No difference
Accucheck
Aviva
42 926 633 £15.5 m Wavesense Jazz (-)£5.15 m No difference
Accucheck
Aviva Nano
42 926 633 £15.5 m Wavesense Jazz (-)£5.15 m No difference
Mendor
discreet
221 000 £75,140 Wavesense Jazz (-)£22,100 (+) Alarms and Notifications
Glucodock
Module
10 300 £3,502 Wavesense Jazz (-)£1,030 (+) 7 and 14 day averages
iCARE
Advanced
Solo
34 300 £10,290 Wavesense Jazz (-)£3,430 (+) USB connectivity, alarms and notifications
Medisense
Softsense
33 800 £11,492 Wavesense Jazz (-)£3,380 (+) USB connectivity, alarms and notifications,
7- and 14-day averages.
Total 199 319 312 £23.2 m
SMBG, self-monitoring of blood glucose.
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Bolus insulin adjustment, for example, is a feature likely to be
used by many, and given the well-documented problems with
incorrect insulin dosing attributable to common numeracy
issues in patients with diabetes [28], such a feature is likely to
be extremely valuable. Other features, such as alternate-site
testing,which only has a favourable evidence basewith respect
to reducing pain and increasing compliance in teens and
adolescents [29], are likely to be of less value to the average
SMBG user. We further appreciate that other more specific
features, not included in the scope of the present analysis, may
be equally importantwhen deciding on the appropriate SMBG
device, including having sufficient monitor memory to satisfy
Driver and Vehicle Licensing Agency requirements [30].
It is also unclear whether manufacturers will be able to
meet increased production demands following the proposed
standardization of SMBG services as these may, to some
extent, prevent the significant savings associated with the
bulk purchase of such a small number of SMBG systems.
Moreover, the limited availability of published post-market
approval surveillance data regarding SMBG monitor accu-
racy mean that, whilst it is possible to confirm that some
SMBG systems do not meet acceptable meter accuracy
standards [18–20], questions remain with respect to the
accuracy of those that are currently being or yet to be
assessed. Because of the small number of SMBG systems used
by the NHS which are yet to be assessed future research, in
the form of independent reviews of meter accuracy, would
almost certainly reduce this uncertainty surrounding the
provision of such technologies. Uncertainty around the ‘true’
price of NHS SMBG testing may also be minimized if the
NHS were to disclose the levels of discount achieved on the
list price. This would not only increase transparency but also
allow wide-scale gains in health service efficiency, enabling a
more accurate assessment of the true costs and benefits of
SMBG technologies, and a more reliable estimation of the
opportunity for cost saving.
The strengthsof thepresent study include thequality and size
of the data used. The HSCIC recorded data on 6.4 million test
strip and 2 million lancet prescriptions, detailing exactly how
eachofthe581millionSMBGteststripsand~150millionlancets
dispensedduringthestudyperiodweredistributed,leavinglittle
room for uncertainty. The studywas also conductedwith strict
referencetoConsolidatedHealthEconomicEvaluationReport-
ing Standards (CHEERS) reporting standards for health
economicoutcomes, andas such, is transparentandcompletely
reproducible in the event that new information comes to light
whichmay affect the conclusions reached.
In conclusion, the study uncovered considerable variation
in the price paid by the NHS for SMBG, which could not be
explained by the availability of advanced meter features. A
standardized approach to SMBG prescribing could achieve
significant efficiency savings for the NHS, whilst increasing
overall utilisation and improving safety for those currently
using SMBG systems that fail to meet acceptable standards of
measurement accuracy.Ta
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